StockNews.AI
TECH
StockNews.AI
118 days

Bio-Techne to Showcase Cutting-Edge Solutions at the 2025 American Association for Cancer Research (AACR) Annual Meeting

1. Bio-Techne to showcase cancer research tools at AACR 2025. 2. Event will feature advanced oncology solutions and technologies. 3. Bio-Techne emphasizes commitment to driving cancer research innovation. 4. Numerous presentations scheduled on advancements in cancer diagnostics. 5. Multiomic solutions expected to enhance drug discovery and patient diagnostics.

9m saved
Insight
Article

FAQ

Why Bullish?

The announcement positions Bio-Techne as a leader in cancer research technologies. Historically, similar showcases in biotechnology led to price increases, as they boost investor confidence in innovation.

How important is it?

The article discusses key advancements in cancer research, which can enhance investor sentiment about Bio-Techne's future growth prospects. The importance score reflects the company's position in an advancing sector amid increasing healthcare investment.

Why Long Term?

Engagement with industry professionals at AACR can lead to partnerships and sales over time, making this impact more relevant in the long run. Previous events have resulted in strong follow-ups in product sales for biotech firms.

Related Companies

TMODHRAVTR
, /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced it will showcase its latest advancements in cancer research tools at the 2025 American Association for Cancer Research (AACR) Annual Meeting, taking place April 25-30 at McCormick Place Convention Center in Chicago, IL. Bio-Techne's booths will feature its oncology research portfolio spanning early discovery, translational research, and cell and gene therapy development. AACR is recognized as one of the world's most influential cancer research conferences, convening global experts to exchange groundbreaking discoveries and innovations in cancer science and medicine. Bio-Techne will engage with these researchers and industry professionals to highlight its cutting-edge solutions that empower scientific progress across the oncology landscape. At booth #3049, Bio-Techne will feature its comprehensive portfolio, including high-performance proteins, antibodies, small molecules, cell culture reagents, immunoassays, automated proteomic analysis platforms, and spatial multiomic solutions. These technologies are designed to drive advancements in oncology research, accelerate immune cell therapy development, and support the creation of next-generation diagnostic tools. Advanced Cell Diagnostics (ACD), a Bio-Techne brand, will feature its complete solution for accelerating spatial multiomic research, including its protease-free workflows across the RNAscope™ spatial portfolio. To support the expanded capabilities for multiomic detection on the Leica Bond RX, we will showcase scientific posters and an evening reception on April 27th co-hosted by ACD, Leica Biosystems and Indica Labs. At booth #3249, Lunaphore, one of Bio-Techne's spatial biology brands, will present its enhanced end-to-end portfolio that offers high-value spatial biology solutions for the translational research community. Lunaphore's latest advancements include the launch of the fully-automated, same-section multiomics application for fixed-frozen tissue. Additionally, Lunaphore will bring together the spatial biology community at an exclusive dinner reception on April 28, held in affiliation with AACR, providing a unique opportunity to connect with leaders in the field of multiomics, and explore Lunaphore's upcoming releases, including innovative tools for HORIZON™ image analysis software. "As cancer research advances at an unprecedented pace, Bio-Techne remains committed to providing scientists with the tools they need to drive discovery and innovation," said Kim Kelderman, Bio-Techne's President and Chief Executive Officer. "Our solutions empower researchers at every stage—from fundamental science to translational applications—helping to shape the future of precision medicine and next-generation cancer therapies. We are excited to connect with the scientific community at AACR to explore new possibilities in the fight against cancer." Bio-Techne Presentations and Poster Presentations: Protein Quantitation for Characterization of Potential Cancer Therapeutics in Early Discovery and Mechanism of Action Insights in Translational StudiesTuesday, April 29 | 10:00 – 11:00 AMExhibit Hall, Spotlight Theater A Evaluation of IDH1, EGFR, IGF1R, and Ki67 Biomarkers in Glioblastoma Using Lunaphore COMET™ PlatformMonday, April 28 | 9:00 AM - 12:00 PMPoster Board 29 | Abstract 2093Presenter: Jennifer Jones, Sr. Product Marketing Specialist Multiomic Co-Detection of Proteins, mRNA and Protein-Protein Interactions Reveal PD1-PDL1 Interactions in the Tumor Microenvironment of Bladder Cancer Patients Treated with anti-PD-L1Monday, April 28 | 9:00 AM - 12:00 PMPoster Board 3 | Abstract 2179Presenter: Ge-Ah Kim, Sr. Scientist Multiomic Fluorescent Co-Detection of Biomarkers in the Tumor Microenvironment Using a New RNAscope™ Assay on Roche DISCOVERY™ ULTRAMonday, April 28 | 9:00 AM - 12:00 PMPoster Board 28 | Abstract 2092Presenter: Anushka Dikshit, Sr. Applications Manager Identifying Immune Cell Phenotypes and Their Function by Using High Throughput Spatial MultiomicsTuesday, April 29 | 2:00 PM - 5:00 PMPoster Board 24 | Abstract 5318Presenter: Anushka Dikshit, Sr. Applications Manager Profiling the Tumor-Immune Landscape with a Same-Section Multiomics AssayTuesday, April 29 | 2:00 PM - 5:00 PMPoster Board 10 | Abstract 5304Presenter: Jacqueline Giliberti, PhD, Product Manager Spatial Multiomics Reveals T-cell Activation and Exhaustion States in the Tumor MicroenvironmentWednesday, April 30 | 9:00 AM - 12:00 PM Poster Board 12 | Abstract 6471Presenter: Anushka Dikshit, Sr. Applications Manager Poster Presentation In CollaborationA Novel Protease-Free Workflow for Spatial Multiomics Analysis of the Tumor Microenvironment in Breast Cancer Poster Board 21 | Abstract 170Presenter: Dr. Tanni Rahman, HistoWiz Dissecting the Immune Landscape in EBV+ Classical Hodgkin Lymphoma Following IL-23 Inhibition Using Single-Cell Hyperplex Immunofluorescence Analysis: A Case Report Wednesday, April 30 | 9:00 AM - 12:00 PM Poster Board 9 | Abstract 6468Presenter: Dr. Janusz Franco-Barraza, Fox Chase Cancer Center Translating clinically Validated Antibodies into a Multiplexed Immunofluorescent Panel for the Spatial Profiling of Lymphoid MalignanciesMonday, April 28 | 2:00 PM - 5:00 PM Poster Board 4 | Abstract 2525Presenter: Dr. Tania Pannellini, European Institute of Oncology (EIO) For more information about Bio-Techne's presence at AACR 2025, visit https://www.bio-techne.com/about/events/aacr. About Bio-Techne Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With hundreds of thousands of products in its portfolio, Bio-Techne generated approximately $1.2 billion in net sales in fiscal 2024 and has approximately 3,100 employees worldwide. For more information on Bio-Techne and its brands, please visit http://www.bio-techne.com or follow the Company on social media at Facebook, LinkedIn, Twitter or YouTube. About Bio-Techne Corporation (NASDAQ: TECH)Contact: David Clair, Vice President, Investor Relations & Corporate Development[email protected] 612-656-4416 SOURCE Bio-Techne Corporation WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In

Related News